Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levetiracetam.

E M Nash1, K S Sangha

  • 1College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|July 14, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dislocated intraocular lens fixation using intraocular cowhitch knot.

American journal of ophthalmology·2001
Same author

Central retinal vein occlusion study.

Indian journal of ophthalmology·1998
Same author

Critical pathways at University of Cincinnati Hospital.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1995
Same author

Pharmacokinetics of once-daily dosing of gentamicin in surgical intensive care unit patients with open fractures.

The Annals of pharmacotherapy·1995
Same author

The physician's role as counselor: when, where and how to make referrals.

Clinical obstetrics and gynecology·1970
Same author

The premarital medical examination and the Carolina population center.

JAMA·1969

Levetiracetam is an effective adjunctive therapy for partial-onset seizures, with excellent oral absorption and minimal drug interactions. Clinical studies confirm its ability to reduce seizure frequency in epilepsy patients.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Epilepsy is a neurological disorder characterized by recurrent seizures.
  • Partial-onset seizures originate in one hemisphere of the brain.
  • Adjunctive therapies are crucial for managing refractory epilepsy.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of levetiracetam.
  • To evaluate levetiracetam as an adjunctive treatment for partial-onset epileptic seizures.

Main Methods:

  • Review of pharmacology, pharmacokinetics, and clinical trial data.
  • Analysis of seizure frequency reduction and adverse event profiles.
  • Assessment of drug interactions and dosage recommendations.

Main Results:

Related Experiment Videos

  • Levetiracetam demonstrates high oral bioavailability (100%) and minimal protein binding.
  • Clinical studies show significant reduction in seizure frequency.
  • Common adverse effects include somnolence and dizziness; drug interactions are minimal.

Conclusions:

  • Levetiracetam is an effective adjunctive treatment for partial-onset epilepsy.
  • Its unique mechanism of action and favorable pharmacokinetic profile support its use.
  • Dosage typically starts at 500 mg twice daily, with a maximum of 3000 mg/day.